A Reevaluation of Risk of In Utero Exposure to Lithium

JAMA: The Journal of the American Medical Association

Volumn 271, Issue 2, 1994, Pages 146-150

  Cohen, Lee S ^a   Friedman, J M ^a   Jefferson, James W ^a   Johnson, E Marshall ^a   Weiner, Myra L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM;

COHORT ANALYSIS; CONGENITAL HEART MALFORMATION; EBSTEIN ANOMALY; FIRST TRIMESTER PREGNANCY; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; NONHUMAN; PRENATAL EXPOSURE; REVIEW; RISK; TERATOGENESIS;

EID: 84942476510     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1994.03510260078033     Document Type: Article

References (49)

1. Jefferson JW, Greist JH, Ackerman DL, Carroll JA, eds. Lithium Encyclopedia for Clinical Practice. 2nd ed. Washington, DC: American Psychiatric Press Inc; 1987:1-31.
2. Jefferson JW. Lithium: a therapeutic magic wand. J Clin Psychiatry. 1989;50:81-86.
3. Weinstein MR. The International Register of Lithium Babies. Drug Information J. 1976;10:94-100.
4. Weinstein MR, Goldfield MD. Administration of lithium during pregnancy. In: Johnson FN, ed. Lithium Research and Therapy. New York, NY: Academic Press Inc; 1975:237-264.
5. Schou M, Goldfield MD, Weinstein MR, Villeneuve A. Lithium and pregnancy, I: report from the Register of Lithium Babies. BMJ. 1973;2:135-136.
6. Kallen B, Tandberg A. Lithium and pregnancy: a cohort study on manic-depressive women. Acta Psychiatr Scand. 1983;68:134-139.
7. Jacobson SJ, Jones K, Johnson X, et al. Prospective multicenter study of pregnancy outcome after lithium exposure during first trimester. Lancet. 1992;339:530-533.
8. Kallen B. Comments on teratogen update: lithium. Teratology. 1988;38:597.
9. Edmonds LD, Oakley GP. Ebstein's anomaly and maternal lithium exposure during pregnancy. Teratology. 1990;41:551-552.
10. Zalstein E, Xoren G, Einarson T, Freedom RM. A case-control study on the association between first trimester exposure to lithium and Ebstein's anomaly. Am J Cardiol. 1990;65:817-818.
11. Sipek A. Lithium and Ebstein's anomaly. Cor Vasa. 1989;31:149-156.
12. Nora JJ, Nora AH, Toews WH. Lithium, Ebstein's anomaly and other congenital heart defects. Lancet. 1974;1:594-595.
13. Suppes T, Baldessarini RJ, Faedda GL, et al. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry. 1991;47:1082-1088.
14. Tohen M, Waternaux CM, Tsuang MT. Outcome in mania: a 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry. 1990;47:1106-1111.
15. Kehrberg G. Study of the prophylactic effect of lithium in radiogenic leucocytopenia. In: Schrauzer GM, Klippel KF, eds. Lithium in Biology and Medicine: New Applications and Developments. Weinheim, Germany: VCH Verlagsgesellschaft; 1991: 47-64.
16. Amsterdam JD, Maislin G, Potter L, Guiunfoli R. Reduced rate of recurrent genital herpes infections with lithium carbonate. Psychopharmacol Bull. 1990;26:843-847.
17. Kirklin JW, Barratt-Boyes BG. Ebstein's malformations. In: Kirklin JW, Barratt-Boyes BG, eds. Cardiac Surgery. New York, NY: John Wiley & Sons Inc; 1986:889-907.
18. Kallen B. Epidemiology of Human Reproduction. Boca Raton, Fla: CRC Press; 1988:61-104.
19. Ferner RE, Smith JM. Lithium in pregnancy. Lancet. 1992;339:869.
20. Kallen B. Lithium therapy and congenital malformations. In: Schrauzer GM, Klippel KF, eds. Lithium in Biology and Medicine: New Applications and Developments. Weinheim, Germany: VCH Verlagsgesellschaft; 1991:121-130.
21. Czeizel A, Racz J. Evaluation of drug intake during pregnancy in the Hungarian case-control surveillance of congenital anomalies. Teratology. 1990;42:505-512.
22. Rosenthal R. The 'file-drawer problem' and intolerance for no results. Psychol Bull. 1979;86:638-641.
23. Robert E, Francannet C. Comments on 'Teratogen Update on Lithium' by J. Warkany. Teratology. 1990;42:205.
24. Nars PW, Girard J. Lithium carbonate intake during pregnancy leading to large goiter in a premature infant. AJDC. 1977;131:924-925.
25. Robert E, Francannet C, Robert JM. Le Registre de malformations de la region Rhone-Alpes/ Auvergne. J Gynecol Obstet Biol Reprod. 1988;17: 601-607.
26. Johnson EMJ. A summary review and human perspective for developmental toxicity evaluations on lithium in laboratory animals. In: Schrauzer GN, Klippel KF, eds. Lithium in Biology and Medicine: New Applications and Developments. Weinheim, Germany: VCH Verlagsgesellschaft; 1991:101-112.
27. Weiner ML. Overview of lithium toxicology. In: Schrauzer GN, Klippel KF, eds. Lithium in Biology and Medicine: New Applications and Developments. Weinheim, Germany: VCH Verlagsgesellschaft, 1991:81-100.
28. McBride WG. Thalidomide and congenital abnormalities. Lancet. 1961;2:1358.
29. Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med. 1985;313:837-841.
30. Paffenbarger RA. Epidemiological aspects of mental illness associated with childbearing. In: Brockington IF, Kumar R, eds. Motherhood and Mental Illness. New York, NY: Grune & Stratton; 1982.
31. Faedda GL, Tondo L, Baldessarini RJ, et al. Outcome after rapid discontinuation of lithium treatment in bipolar mood disorders. Arch Gen Psychiatry. 1993;50:448-455.
32. Jefferson JW, Greist JH. Lithium in psychiatric practice. In: Adelman G, ed. Encyclopedia of Neuroscience. Boston, Mass: Birkhauser Boston; 1987: 592-593.
33. Reifman A, Wyatt RJ. Lithium: a brake in the rising cost of mental illness. Arch Gen Psychiatry. 1980;37:385-388.
34. Robins LN, Heizer JE, Weissman MM. Lifetime prevalence of specific psychiatric disorders. Arch Gen Psychiatry. 1984;41:949-958.
35. Cohen LS, Heller VL, Rosenbaum JF. Treatment guidelines for psychotropic drug use in pregnancy. Psychosomatics. 1989;30:389-405.
36. Cohen LS, Rosenbaum JF, Heller VL. Psychotropic drug use in pregnancy. In: Gelenberg AJ, Bassuk EL, Schoonover SC, eds. The Practitioner's Guide to Psychoactive Drugs. New York, NY: Plenum Medical Book Co; 1991:389-405.
37. Cohen LS, Rosenbaum JF, Heller VL. Prescribing lithium for pregnant women. Am J Psychiatry. 1988;145:773.
38. Sitland-Marken PA, Rickman LA, Wells BG, et al. Pharmacologic management of acute mania in pregnancy. J Clin Psychopharmacol. 1989;9:78-87.
39. Langman J. Medical Embryology. 2nd ed. Baltimore, Md: William & Wilkins; 1975.
40. Dicke JM. Teratology: principles and practice. Med Clin North Am. 1989;73:567-581.
41. Markovitz PJ, Calabrese JR. Use of anticonvulsants for manic depression in pregnancy. Psychosomatics. 1990;31:118.
42. Jones KL, Lacro RV, Johnson KA, et al. Pattern of malformations in the children of women treated with carmazepine during pregnancy. N Engl J Med. 1989;320:1661-1666.
43. Lindhout D, Schmidt D. In utero exposure to valproate and neural defects. Lancet. 1986;1:329-393.
44. Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects. Lancet. 1982; 2:934.
45. Milkovich L, Van den Berg BJ. An evaluation of the teratogenicity of certain antinauseant drugs. Am J Obstet Gynecol. 1976;125:244-248.
46. Edlund MJ, Craig TJ. Antipsychotic drug use and birth defects: an epidemiologic reassessment. Compr Psychiatry. 1984;25:32-37.
47. Slone D, Siskind V, Heinomen OP, et al. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol. 1977;128:486-488.
48. Rumeau-Rouguette C, Goujard J, Huel G. Possible teratogenic effect of phenothiazines in human beings. Teratology. 1977;15:57-64.
49. Casey DE. Tardive dyskinesia. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987:1411-1417.